v3.26.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Research and development expenses $ 6,620,323 $ 4,926,936 $ 11,852,864 $ 9,508,608
Acquisition-related costs   3,086,982   3,506,025
General and administrative expenses 2,142,961 1,862,038 4,440,319 3,878,346
Operating Loss (8,763,284) (9,875,956) (16,293,183) (16,892,979)
Other (Expense) Income:        
Grant income   322,655   575,209
Interest expense (467,634)   (495,608)  
Interest income 7,620 29,466 28,895 129,564
Total Other (Expense) Income (460,014) 352,121 (466,713) 704,773
Net Loss (9,223,298) (9,523,835) (16,759,896) (16,188,206)
Series A Preferred cash dividend (2,089) (2,089) (4,178) (4,178)
Net Loss attributable to common stockholders $ (9,225,387) $ (9,525,924) $ (16,764,074) $ (16,192,384)
Net Loss per share, basic $ (0.14) $ (0.21) $ (0.27) $ (0.36)
Net Loss per share, diluted $ (0.14) $ (0.21) $ (0.27) $ (0.36)
Weighted-average shares outstanding, basic 63,963,513 44,555,095 61,997,795 44,983,198
Weighted-average shares outstanding, diluted 63,963,513 44,555,095 61,997,795 44,983,198